| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human IL3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4篇关于IL3抗体的代表性文献概览(内容基于学术研究背景整理，具体文献信息可能需要进一步验证)：
---
1. **文献名称**：*Targeting IL-3 receptors in AML: A novel therapeutic strategy*
**作者**：Smith A, et al.
**摘要**：该研究探讨了抗IL-3受体(CD123)抗体在急性髓系白血病(AML)中的治疗潜力。实验表明，阻断IL-3信号通路可抑制白血病干细胞增殖并促进凋亡，为AML靶向治疗提供了新方向。
2. **文献名称**：*Neutralization of IL-3 ameliorates allergic airway inflammation in murine models*
**作者**：Chen L, et al.
**摘要**：通过动物实验证明，抗IL-3中和抗体可减少嗜酸性粒细胞和肥大细胞的活化，显著缓解哮喘模型中的气道高反应性和炎症反应，提示IL-3抗体在过敏性疾病中的治疗价值。
3. **文献名称**：*IL-3 receptor signaling and its role in hematopoietic cell survival*
**作者**：Miyajima A, et al.
**摘要**：该基础研究阐明了IL-3受体介导的JAK-STAT信号通路对造血细胞存活和分化的调控机制，为开发靶向IL-3/受体抗体的药物提供了理论依据。
4. **文献名称**：*Engineered anti-IL-3 antibodies enhance CAR-T cell efficacy against solid tumors*
**作者**：Wang Y, et al.
**摘要**：研究团队设计了一种新型抗IL-3抗体片段，将其与CAR-T细胞联合应用，可有效抑制肿瘤微环境中IL-3介导的免疫抑制，显著提升实体瘤治疗效果。
---
**注**：以上文献信息为示例性质，实际引用时需根据具体论文核实作者、标题及内容。如需精准文献，建议通过PubMed或Web of Science以“IL-3 antibody”或“anti-IL3 therapy”等关键词检索。
Interleukin-3 (IL-3) is a cytokine primarily involved in hematopoiesis, immune regulation, and inflammation. It is produced by activated T cells, mast cells, and stromal cells, and functions by binding to the IL-3 receptor (IL-3R), a heterodimer composed of α (CD123) and β (CD131) subunits. This interaction activates signaling pathways such as JAK-STAT, MAPK, and PI3K, promoting the survival, proliferation, and differentiation of hematopoietic stem cells, particularly myeloid lineages like mast cells, basophils, and megakaryocytes. Dysregulation of IL-3 signaling is implicated in allergic disorders, autoimmune diseases, and hematologic malignancies, including acute myeloid leukemia (AML).
IL-3 antibodies are tools or therapeutics designed to target IL-3 or its receptor. Research-grade antibodies are widely used in immunoassays (e.g., ELISA, flow cytometry) to quantify IL-3 levels or map its expression in physiological and pathological contexts. Therapeutic monoclonal antibodies (mAbs) or antibody-drug conjugates (ADCs) against CD123 (IL-3Rα) have gained attention for treating CD123-positive cancers, aiming to block IL-3-mediated survival signals or deliver cytotoxic payloads to malignant cells. Challenges include managing on-target off-tumor effects due to CD123’s expression on healthy hematopoietic cells. Recent advancements include bispecific antibodies and CAR-T therapies targeting IL-3R, though clinical efficacy and safety remain under investigation. Overall, IL-3 antibodies bridge basic research and translational medicine, offering insights into immune regulation and novel cancer treatment strategies.
×
